OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentblue cross blue shield - kansasPolicy N/A

Contrast-Enhanced Coronary Computed Tomography Angiography (CCTA) for Coronary Artery Evaluation

Customize your policy alerts

Sign up for all blue cross blue shield - kansas policy alerts

Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs the medical necessity and coverage criteria for contrast-enhanced coronary CT angiography (CCTA) to evaluate coronary arteries for Blue Cross Blue Shield of Kansas members, including use in acute chest pain, stable chest pain, and suspected anomalous coronary arteries.

Policy Summary

Payerblue cross blue shield - kansas

PolicyContrast-Enhanced Coronary Computed Tomography Angiography (CCTA) for Coronary Artery Evaluation

Policy CodePolicy N/A

Change TypeNo material change

Effective DateNov 9, 2022

Last ReviewDec 9, 2025

Next Review DateDec 9, 2025

Key ActionVerify member benefits and any prior authorization requirements and document indication, pretest probability, and rationale for choosing CCTA in the medical record.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3major indications addressed

93–97%CCTA sensitivity range

high NPVhigh NPV supports ED rule-out

75574primary CPT code listed

NCT04748237ongoing ED RCT enrollment

Coverage Criteria and Evidence Summary

inv-01: Medically Necessary Indications — Covered when the following specific indications are met:

Covered when the following specific indications are met:

Medically Necessary Indications: Contrast-enhanced CCTA is medically necessary for: (A) evaluation of individuals without known coronary artery disease presenting with acute chest pain in the emergency department; (B) evaluation of individuals with stable chest pain who meet guideline criteria for a noninvasive test in the outpatient setting; (C) evaluation of individuals with suspected anomalous (native) coronary arteries.

Policy A–C

inv-02: Experimental / Investigational Indications — Not covered:

Not covered:

Experimental/Investigational: Contrast-enhanced CCTA for coronary artery evaluation is considered experimental/investigational for all indications not listed as medically necessary.

Policy D

Policy Summary

Payerblue cross blue shield - kansas

PolicyContrast-Enhanced Coronary Computed Tomography Angiography (CCTA) for Coronary Artery Evaluation

Policy CodePolicy N/A

Change TypeNo material change

Effective DateNov 9, 2022

Last ReviewDec 9, 2025

Next Review DateDec 9, 2025

Key ActionVerify member benefits and any prior authorization requirements and document indication, pretest probability, and rationale for choosing CCTA in the medical record.

SourceLink

On This Page

inv-03: Clinical evidence summary / coverage-relevant criteria — Summary of evidence-based clinical considerations for CCTA in ED acute chest pain

Summary of evidence-based clinical considerations for CCTA in ED acute chest pain

Evidence and population: Applicable to ED patients with acute chest pain and suspected CAD who are low- to intermediate-risk; outcomes of interest include mortality, diagnostic accuracy, and utilization of invasive coronary angiography (ICA) assessed in the short term and over longer-term follow-up.

Chunks 18,21

Clinical utility findings: Systematic reviews and randomized trials show CCTA can reduce ED length of stay and costs and may decrease additional ED testing versus usual care, but may increase revascularization and referral for ICA compared with some comparators; no consistent differences in MI or mortality have been demonstrated.

Chunks 26,30

Evidence limitations: Diagnostic characteristics of CCTA in ED populations are limited by verification bias and heterogeneity of standard-of-care comparators across trials, which limits direct estimation of diagnostic accuracy and generalizability.

Chunks 23 (implicit), 30

inv-04: Medically Necessary Uses — Covered when ALL of the following are met

Covered when ALL of the following are met

Indication: Patient presents with acute chest pain in the ED where CCTA is being used to rule out coronary artery disease OR patient has stable chest pain with suspected CAD and meets guideline criteria for noninvasive testing in the outpatient setting.

Chunks 52,53,55

Documentation: Clinical presentation, pretest probability or risk assessment, and rationale for selecting CCTA (eg, anatomic-first vs functional-first approach) are documented in the medical record.

Chunks 54,55

inv-05: Coverage criteria for CCTA in stable chest pain — Covered when ALL of the following are met

Covered when ALL of the following are met

Population: Individual has stable chest pain with suspected coronary artery disease and is at intermediate pre-test risk meeting guideline criteria for noninvasive testing.intermediate pre-test risk

Chunks 55,54

Test selection: CCTA is selected as the noninvasive diagnostic test to evaluate coronary artery obstruction as an alternative to functional testing (exercise ECG, myocardial perfusion imaging, or stress echocardiography) based on guideline considerations and patient suitability.

Chunks 57,54

inv-06: CCTA diagnostic accuracy and trial outcome summary — Summary conclusions from randomized trials and diagnostic accuracy evidence

Summary conclusions from randomized trials and diagnostic accuracy evidence

Diagnostic performance: Meta-analyses report CCTA sensitivity >95% for detecting anatomic coronary disease with specificity comparable to other noninvasive tests, supporting high diagnostic accuracy for anatomic disease detection.

Chunk 97

Clinical outcomes trials: Randomized clinical trials generally have not shown superiority of CCTA over other strategies for clinical outcomes; trials suggest similar or noninferior outcomes and variable effects on rates of ICA and revascularization depending on comparator and trial design.

Chunk 97

Trial limitations: Heterogeneous comparator strategies, differences in trial design, and variable generalizability (eg, population exclusions) limit strength of conclusions regarding outcome superiority.

Chunk 97

inv-07: CCTA for suspected anomalous coronary arteries — Use of CCTA for suspected anomalous coronary arteries

Use of CCTA for suspected anomalous coronary arteries

Intended population: Individuals with suspected anomalous native coronary arteries (anomalies occur in ~1% of coronary angiograms).

Chunks 98,100

Intervention: CCTA performed to delineate the course of anomalous coronary arteries when suspected clinically or when conventional angiography is inconclusive.

Chunks 101,108

Evidence and outcomes: Evidence consists of case series showing CCTA can delineate anomalous courses even when conventional angiography cannot; no randomized trials assess clinical utility or impact on management or outcomes.

Chunks 107,109

inv-08: Clinical scenarios where CCTA may be appropriate — Situations described in the document where CCTA may be appropriate or has been evaluated:

Situations described in the document where CCTA may be appropriate or has been evaluated:

Anomalous coronary arteries: CCTA delineates the course of anomalous coronary arteries and is appropriate when anomalies are suspected or conventional angiography is inconclusive (evidence from case series).

Chunks 108-109

Graft patency evaluation: CCTA has high sensitivity and specificity for evaluating vein graft patency, although imaging internal mammary grafts and distal native vessels may be more challenging.

Chunk 111

In-stent restenosis: CCTA assessment of in-stent restenosis is technically challenging (motion, beam-hardening, partial volume averaging) and accuracy/impact on outcomes is not well demonstrated.

Chunk 112

Screening asymptomatic populations: Screening low-risk asymptomatic populations with CCTA increased downstream testing and treatment without reducing cardiac event rates in trials (eg, McEvoy 2011; FACTOR-64 showed no primary outcome benefit).

Chunks 113-114

Preoperative evaluation: CCTA can stratify perioperative MACE risk by severity of CAD, but clinical utility to change management or reduce events is unclear and prior trials have not shown benefit of preoperative revascularization or medical therapy to reduce MACE.

Chunk 114

Acute chest pain / ED use: Guidelines (ACC, SCCT) support CCTA for selected ED patients (eg, low-to-intermediate risk to rule out ACS, prior CABG or prior PCI with certain stents to evaluate graft/stent patency) and advise against CCTA when immediate reperfusion for STEMI and door-to-balloon time <90 minutes is required.

Chunks 117,122,123

Stable chest pain: Guidelines indicate CCTA may be appropriate as a first-line or confirmatory test in stable chest pain patients without known CAD, particularly when functional testing is inconclusive or patient cannot exercise or has an uninterpretable ECG.

Chunks 120,122

inv-09: Medically Necessary Indications (alternate listing) — Covered when guideline-based criteria are met:

Covered when guideline-based criteria are met:

Outpatient stable symptoms: Contrast-enhanced CCTA is medically necessary for evaluation of patients with symptoms of stable ischemic heart disease who meet guideline criteria for a noninvasive test in the outpatient setting (see Policy Guidelines and pretest probability tables).see Policy Guidelines

Chunks 136,137

Acute chest pain in ED: Contrast-enhanced CCTA is medically necessary for evaluation of individuals without known CAD presenting with acute chest pain in the ED when ECG is non-diagnostic and serial enzymes are negative, consistent with guideline-based intermediate pre-test probability.intermediate pre-test probability

Chunks 134,136

Anomalous coronary arteries: Contrast-enhanced CCTA is medically necessary for evaluation of individuals with suspected anomalous (native) coronary arteries when clinical suspicion exists.clinical suspicion

Chunk 138

inv-10: Not Medically Necessary / Investigational — Not covered / investigational for other indications:

Not covered / investigational for other indications:

Other indications: Contrast-enhanced coronary computed tomography angiography is considered experimental/investigational for all other indications not specified as medically necessary.N/A

Chunks 136,138

This policy addresses the use of contrast-enhanced coronary computed tomography angiography (CCTA) for coronary artery evaluation. CCTA is considered medically necessary for three indication groups: (A) evaluation of individuals without known coronary artery disease presenting with acute chest pain in the emergency department; (B) evaluation of individuals with stable chest pain who meet guideline criteria for a noninvasive test in the outpatient setting; and (C) evaluation of individuals with suspected anomalous (native) coronary arteries. Use of CCTA for coronary evaluation outside these specified indications is considered experimental/investigational and not covered.

Diagnostic performance data for CCTA in ED populations are affected by verification bias: patients with negative CCTA are frequently discharged and true disease status may remain unknown, so diagnostic characteristics cannot be directly determined in ED studies. Prior diagnostic accuracy estimates come from other settings and were applied in randomized trials assessing clinical utility rather than deriving ED-specific sensitivity/specificity.

CCTA findings alone are insufficient to establish clinical utility; when CCTA is used as an anatomic-first diagnostic strategy, the medical record must document the clinical management plan that follows the anatomic results (eg, criteria for proceeding to invasive coronary angiography or medical therapy), because patient outcomes depend not only on test results but also on subsequent treatment decisions.

Clinical validity evaluations and studies used to support coverage must report the accuracy of the marketed version of the technology, include a suitable reference standard (for example, invasive coronary angiography), and describe patient selection and clinical characteristics. Studies or applications that do not document the marketed device/version, an appropriate reference standard, or clear patient selection criteria have limited applicability for coverage determinations.

Randomized trials and systematic reviews included in this review have design and population limitations that affect generalizability: some trials were conducted only in European populations, others excluded older adults (eg, >75 years), some had high proportions of specific racial/ethnic groups, and several had limited duration of follow-up or incomplete reporting of harms. These relevance and generalizability issues should be considered when applying trial results to local practice.

Although case series show CCTA can delineate the course of anomalous coronary arteries, no randomized controlled trials were identified in which CCTA was performed specifically to detect anomalous coronary arteries. The available evidence consists of case series and lacks prospective data on how imaging affected therapeutic decisions or patient outcomes.

Guidance from professional societies notes that CCTA is usually not appropriate when the ECG is diagnostic for STEMI and immediate reperfusion is indicated; in such cases door-to-balloon time of 90 minutes should be prioritized over performing CCTA.

Historical policy language listed technical contraindications and limitations that can affect CCTA performance, including high body mass index (eg, BMI > 40), inability to image at the desired heart rate, presence of atrial fibrillation or other significant arrhythmia, and extensive coronary calcification (historically noted as Angston score >1700). These specific exclusions were removed or revised in later updates, but they reflect known technical limitations that may reduce image quality and diagnostic accuracy.

Use of contrast-enhanced CCTA for indications other than the specific scenarios enumerated as medically necessary (ED acute chest pain without known CAD, guideline-based stable chest pain, and suspected anomalous coronary arteries) is considered not medically necessary / experimental or investigational. Claims for other indications may be denied if the requested use is outside the policy’s listed indications.

Routine use of CCTA outside guideline-recommended populations — for example, using CCTA broadly in low-risk asymptomatic individuals or without documentation of pretest probability — is not supported by the evidence. Randomized and systematic reviews show CCTA increases new diagnoses and downstream invasive testing in some settings without consistent improvements in hard outcomes when used outside recommended populations.

Systematic reviews and randomized trials have not consistently demonstrated that CCTA improves mortality or hospitalization compared with functional testing. Trials and meta-analyses report similar overall mortality and cardiac hospitalization between CCTA and functional testing arms, although CCTA is associated with higher rates of ICA and revascularization in some analyses.

Because randomized clinical trials are lacking for the use of CCTA to evaluate suspected anomalous coronary arteries, the evidence base is limited to case series that document anatomic delineation but do not provide randomized outcome data. This lack of RCT evidence may limit coverage decisions when demonstrable improvements in patient outcomes are required.

Population screening with CCTA in low-risk asymptomatic individuals has been associated with increased downstream testing and treatment without reduction in cardiac event rates (eg, McEvoy 2011). Similarly, preoperative and screening trials (eg, FACTOR-64) did not show improvements in primary clinical outcomes, underscoring that population screening in low-risk asymptomatic groups is not supported.

Contrast-enhanced CCTA is considered experimental/investigational for indications other than the specific medically necessary scenarios enumerated in this policy. This policy stance applies to any coronary CT angiography use not explicitly listed as medically necessary.

Appropriate and Covered Indications

inv-82: Appropriate clinical indications for CCTA — 3 top-level nodes

Acute Chest Pain in ED: Individuals without known coronary artery disease presenting with acute chest pain in the emergency department at low- to intermediate-risk (eligible for diagnostic testing after initial negative or inconclusive evaluation for ACS).intermediate to low risk

Chunks 12,18

Stable Chest Pain: Individuals with stable chest pain in the outpatient setting who meet guideline criteria for a noninvasive test (eg, intermediate pretest probability per guideline tables).meet guideline criteria

Chunk 4

Suspected Anomalous Coronary Arteries: Individuals with suspected anomalous native coronary arteries where anatomic delineation by CCTA would influence management.clinical suspicion

Chunk 12

inv-83: Evaluation of suspected coronary artery disease in acute chest pain in ED — 1 top-level node

Indication: ED acute chest pain: Patients presenting to the ED with acute chest pain and suspected ACS/CAD who are low- to intermediate-risk and require further risk stratification may be considered for CCTA; randomized trials (eg, RAPID-CTCA, CARMENTA, ROMICAT II) have enrolled such patients with varying inclusion criteria.

Chunks 32,34

inv-84: Appropriate clinical indications — 2 top-level nodes

ED chest pain: Acute chest pain presentation in the ED where CCTA can safely rule out coronary disease and permit rapid discharge when negative; consider ICA rates, radiation and incidental findings in decision-making.

Chunk 52

Stable chest pain intermediate risk: Stable chest pain with suspected CAD and intermediate pre-test probability meeting guideline criteria for noninvasive testing; CCTA may be used as an anatomic-first strategy or alternative to functional testing.

Chunks 55,53

inv-85: Stable chest pain with suspected CAD and intermediate pre-test probability — 1 top-level node

Indication: Patient with stable chest pain and suspected CAD at intermediate pre-test probability where noninvasive testing is indicated.intermediate pre-test probability

Chunks 55,54

inv-86: Stable chest pain or suspected coronary artery disease — 1 top-level node

Stable chest pain or suspected CAD: Randomized trials in intermediate-risk stable chest pain populations compared CCTA strategies with functional testing or usual care, informing noninferiority conclusions for clinical outcomes and differences in ICA/revascularization rates.

Chunks 74,75

inv-87: Evaluation of suspected CAD or suspected anomalous coronary arteries — 1 top-level node

Evaluation of suspected CAD or anomalous arteries: CCTA demonstrates high sensitivity for anatomic CAD (>95%) and is used to evaluate suspected anomalous coronary arteries (evidence for anomalies primarily from case series); no RCTs for anomalous arteries exist.

Chunks 97,98,107

inv-88: Appropriate/considered uses per guideline and evidence summary — 3 top-level nodes

Guideline-based appropriate uses: Major guideline documents (ACC, SCCT) support CCTA for selected patients: intermediate-risk ED patients to exclude ACS, first-line or alternative testing in stable chest pain when functional testing is inappropriate or inconclusive, evaluation of graft patency and selected post-revascularization scenarios, and assessment of coronary anomalies.

Chunks 117,122,123

Restrictions: CCTA is usually not appropriate when ECG is diagnostic for STEMI and door-to-balloon time <90 minutes should be prioritized.

Chunk 123

Pretest probability guidance: Policy guidance references pretest probability tables (eg, Framingham, ACC criteria) to define intermediate risk for selection of CCTA in stable and acute settings.

Chunks 134,136

inv-89: Appropriate indications per policy — 1 top-level node

Policy appropriate indications: CCTA is appropriate to rule out coronary disease in ED patients with low-to-intermediate risk and to evaluate patients with stable symptoms who meet guideline criteria for noninvasive testing; documentation of indication and pretest probability is required.

Chunk 52

inv-90: Clinical indications discussed in the literature cited — 1 top-level node

Literature-covered indications: Cited literature and trials address acute chest pain evaluation, stable chest pain/angina assessment, revascularization decision-making, graft patency evaluation, and coronary anomalies; these form the evidence base informing policy indications.

Chunks 144,149,151

Not Medically Necessary / Investigational Uses

CCTA for coronary artery evaluation that is requested for indications other than those specified as medically necessary in this policy is considered experimental/investigational and therefore not covered.

CCTA performed in populations that do not meet guideline criteria or when a documented pretest probability assessment is not provided is not supported by this policy and is considered not covered.

Additional statements in the policy reiterate that uses outside the defined medically necessary indications are investigational; such requests may be denied as not covered unless supporting evidence and documentation meet the policy’s requirements for investigational use.

Consistent with the policy’s investigational stance, CCTA requests for indications not explicitly listed as medically necessary should be considered not covered; documentation and justification may be requested but do not guarantee approval when the indication falls outside policy criteria.

In summary, CCTA for all other indications not specifically listed as medically necessary in this policy is considered experimental/investigational and not covered.

Procedure Codes and Performance Notes

Included procedure codesCPT

75574

Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image post processing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)

Covered CPT Codes (informational list)CPTCovered

75574

System performance summary — vein graft patency

Vein graft patency (segment-level)Sensitivity 98%; Specificity 97% (pooled estimate from systematic review of 64-slice scanners).

Scanner generationPerformance reported from studies using 64-slice multidetector CT scanners.

Evidence sourcePooled data reported by Stein et al (2008) systematic review.

Pre-test probability — intermediate risk

Pre-test probability rangeIntermediate pre-test probability by Framingham risk scoring: 10%–20%.

Alternative criteriaAlso referenced: American College of Cardiology (ACC) criteria for intermediate pre-test probability (see Policy Guidelines).

Context of useApplied to evaluation of acute chest pain in ED and stable chest pain when selecting CCTA as noninvasive test.

Provider Responsibilities, Prior Authorization, and Documentation

Prior Authorization

Prior authorization verification

Verify member benefits, state and federal mandates, and any prior authorization requirements with Blue Cross and Blue Shield of Kansas Customer Service before scheduling CCTA. Member contract language takes precedence over this policy.

Contact BCBSKS Customer Service to confirm member eligibility and any prior authorization requirements
State/federal mandates and member contract provisions may override policy coverage

Prior Authorization

Prior authorization — evidence context

Evidence from randomized controlled trials and systematic reviews supports clinical use of CCTA for specific indications (acute chest pain in the ED, intermediate‑risk stable chest pain, and suspected anomalous coronary arteries). Prior authorization decisions that require evidence context should note the RCT and systematic review findings (e.g., reduced length of stay and costs, increased downstream revascularization in some trials, and mixed effects on ICA and clinical outcomes).

Key evidence sources include living systematic reviews/meta-analyses and multiple RCTs (RAPID-CTCA, CARMENTA, PROMISE, SCOT-HEART, DISCHARGE, RESCUE, CONSERVE, etc.)
Consider trial-specific outcomes: length of stay, costs, downstream ICA/revascularization, MI, and mortality

Prior Authorization

Prior authorization for appropriate clinical use

Prior authorization, when required by the plan, should confirm that the intended use aligns with the policy's medically necessary indications: acute ED chest pain, stable chest pain meeting guideline criteria for noninvasive testing, or suspected anomalous native coronary arteries. Requests for other indications should be considered investigational per this policy.

Medically necessary indications per Policy: ED acute chest pain; stable chest pain meeting guideline criteria; suspected anomalous coronary arteries
All other indications are considered experimental/investigational

Prior Authorization

Prior authorization for intermediate-risk stable chest pain

For outpatient stable chest pain, prior authorization should document that the patient is at intermediate pretest probability of CAD and meets guideline criteria for noninvasive testing before approving CCTA as the initial or anatomic-first strategy.

Confirm patient meets guideline criteria for noninvasive testing (intermediate-risk stable chest pain)
Document rationale if CCTA is used as an anatomic-first strategy instead of functional testing

Billing Rule

Procedure code requiring policy-aligned performance

When prior authorization or medical necessity review is performed, ensure that the procedure code submitted (CPT 75574) corresponds to a study performed according to the Policy (contrast-enhanced coronary CTA with 3D postprocessing). Claims for 75574 are considered medically necessary only if the study meets Policy criteria.

CPT 75574: Computed tomographic angiography, heart, coronary arteries and bypass grafts, with contrast, including 3D post processing
Code is medically necessary ONLY when performed according to this Policy

Billing Rule

Procedure code applicability

CPT code 75574 applies to contrast-enhanced coronary CTA with 3D image postprocessing and is the applicable code listed in this policy. Inclusion of the code here is informational; coverage depends on member contract and that the procedure was performed per the Policy.

75574 — CT angiography, heart/coronary arteries with contrast and 3D postprocessing
Inclusion of a code does not guarantee member coverage or reimbursement

Note

Prior authorization not specified in this section

This Provider Actions section does not specify a universal prior authorization requirement; providers must verify with BCBSKS whether prior authorization is required for an individual member and indication.

Policy itself does not state a mandatory prior authorization step — check member benefits
Verify prior auth requirements for the specific plan and indication before service

Denial Risk

Denial risk for non-covered indications

CCTA is considered experimental/investigational for indications other than those listed in the Policy. Claims for non‑covered indications may be denied under this policy.

Non-listed indications = experimental/investigational and may be denied
Document clinical rationale if requesting coverage for atypical indications

Documentation Required

Follow-up testing and incidental findings

Document and justify expected downstream testing and management plans. Incidental findings on CCTA are common and may prompt additional diagnostic testing or interventions; prior authorization reviewers should consider the likelihood of follow-up testing and its clinical rationale.

Document plan for follow-up testing if incidental findings are anticipated
Acknowledge that subsequent invasive testing may be more frequent after CCTA in some studies

Note

None specified in this section

None specified in this section beyond the above actionable items; use the Policy and member contract to guide prior authorization and documentation requirements.

No additional provider actions specified in this subsection

Documentation Required

Indication documentation

Include the clinical indication in the authorization or claim: acute chest pain in the ED or stable chest pain with intermediate pretest probability, and clearly state the intended management pathway (e.g., diagnostic rule-out, guide revascularization decisions, or delineation of anomalous coronary anatomy).

Document whether indication is ED acute chest pain or stable chest pain with intermediate pretest probability
State intended management decision or next steps based on CCTA results

Note

Trial reports include site, country, dates

When submitting evidence or clinical trial information to support a request, include trial/site details (site, country, and dates) and participant/intervention descriptions to match the study-selection and trial-reporting expectations used in this policy.

Provide study identifiers, sites, countries, and enrollment dates when citing trials
Include participant eligibility and intervention/comparator descriptions

Note

Evidence submission details

For evidence submissions, include the marketed technology version, a suitable reference standard, patient characteristics, selection criteria, and outcomes as described in the Study Selection and Evidence Submission criteria of this policy.

Report the marketed version of the CCTA technology and any algorithms used
Include reference standard (eg, invasive coronary angiography) and detailed patient/sample characteristics

Documentation Required

Documentation and medical necessity note

Procedures and claims for listed codes will be considered medically necessary only if performed and documented in accordance with the Policy. Verify member contract benefits; the presence of a code in this document does not guarantee coverage.

All coronary CTA studies must be performed per Policy to be considered medically necessary
Verify member contract benefits at time of service

Documentation Required

Documentation requirement (historical note)

Historically, a Documentation section was added noting that all coronary CTA studies will be documented per policy. Maintain required documentation elements (indication, findings, impact on management) consistent with the policy's Documentation expectations.

Historical note: Documentation section added that all coronary CTA studies will be documented per policy
Ensure reports include indication, technique, findings, and how results guide management

Note

Bibliographic and committee references for Blue Cross and Blue Shield of Kansas

Blue Cross and Blue Shield of Kansas cardiology and radiology liaison and medical advisory committees have been engaged in policy development and review; bibliographic and committee references are listed for historical and contact context.

BCBSKS Cardiology Liaison Committee and Radiology Liaison Committee meeting dates listed historically
Medical Advisory Committee meeting dates also provided

Note

Comparators / alternative testing

Comparators to CCTA include standard ED care, exercise ECG, myocardial perfusion imaging (MPI), stress echocardiography, and invasive coronary angiography depending on clinical context. Prior authorization reviewers should consider whether an alternative noninvasive or functional test is more appropriate for the patient.

ED/standard care and various noninvasive functional tests (exercise ECG, MPI, stress echo) are common comparators
Consider if CCTA is being requested as a substitute for or adjunct to these alternatives

Documentation Required

Anatomic-first vs functional-first rationale

If claim review or authorization questions clinical strategy, document the rationale for an anatomic-first (CCTA) versus functional-first approach, including patient-specific factors (ECG interpretability, ability to exercise, pretest probability) that support choosing CCTA.

Document clinical rationale for anatomic-first vs functional-first testing
Include factors such as ECG interpretability, exercise capacity, and pretest probability

Note

Position among noninvasive tests

Position CCTA among noninvasive tests by documenting why CCTA is preferred for the individual patient (eg, high sensitivity for anatomic disease, ability to delineate anatomy or anomalous coronaries, rapid ED rule-out), and note limitations such as potential downstream testing, radiation exposure, and incidental findings.

Highlight CCTA strengths (high sensitivity for anatomic disease, anatomical delineation) and limitations (downstream ICA, incidental findings, radiation)
Explain why other noninvasive tests are less suitable for this patient

Contrast and Technical Notes

Billing Rule

Use FDA‑cleared IV iodinated contrast for CCTA

Providers must use intravenously administered iodinated contrast agents cleared by the FDA when performing CCTA; the procedure involves contrast-enhanced acquisition to visualize coronary anatomy.

Ensure use of FDA‑cleared IV iodinated contrast agents for CCTA.
Document contrast administration as part of the procedure.

Note

Identify the intervention as contrast‑enhanced CCTA

The procedure of interest is contrast‑enhanced coronary CT angiography (CCTA); orders and authorization requests should reference that the intervention is contrast‑enhanced CCTA.

Specify that the imaging study is contrast-enhanced coronary CT angiography when requesting authorization or scheduling.

Billing Rule

Document contrast‑enhanced acquisition

CCTA is performed with iodinated intravascular contrast to visualize coronary artery anatomy; documentation should note that a contrast‑enhanced acquisition was performed.

Record that iodinated intravascular contrast was administered and used for coronary artery visualization.

Note

Billing Rule

CCTA coverage tied to contrast‑enhanced performance per Policy

The policy covers contrast‑enhanced CCTA (CPT 75574) including 3D postprocessing when performed according to the Policy section; ensure the study and billing reflect policy‑aligned performance.

If billing 75574, confirm the study included contrast-enhanced coronary CTA and any 3D postprocessing performed per Policy.
Verify that medical record documentation aligns with Policy indications for medical necessity.

Billing Rule

Ensure billing matches contrast‑enhanced CCTA modality

The CCTA described in this policy is contrast‑enhanced computed tomographic angiography of the heart/coronary arteries (code 75574); billing and documentation should reflect this modality.

Use CPT 75574 when the study is contrast‑enhanced coronary CTA with 3D postprocessing as described.
Ensure coding mirrors the procedure performed and Policy requirements.

Note

Key Definitions

CCTA — contrast-enhanced CTA definition

DefinitionContrast-enhanced coronary computed tomography angiography (CCTA) is a noninvasive imaging test using intravenously administered iodinated contrast and high-resolution, high-speed CT to obtain volumetric images of coronary vessels.

PurposeUsed to visualize coronary artery lumen, stenoses, and plaque to aid diagnosis of coronary artery disease and guide management decisions.

Contrast requirementRequires IV iodinated contrast material as part of the acquisition protocol.

Obstructive CAD — definition

Obstructive CAD definitionArterial stenosis of >50% to 70% diameter, considered significant when accompanied by symptoms.

Clinical relevanceObstructive lesions guide decisions about revascularization and invasive angiography.

Imaging implicationCCTA quantifies arterial stenoses to detect obstructive disease; thresholds vary by studies and guidelines.

Outcomes of interest

Primary outcomesMortality and major adverse cardiac events (MACE) over short- and long-term follow-up.

Diagnostic outcomesDiagnostic accuracy metrics including sensitivity, specificity, negative predictive value, and downstream utilization (eg, rates of ICA and revascularization).

Utilization metricsLength of stay, downstream testing, rates of invasive coronary angiography and revascularization, and medication changes.

Population — ED acute chest pain population definition

PopulationIndividuals presenting to the emergency department with acute chest pain and suspected coronary artery disease who are low- to intermediate-risk.

Stable chest pain subgroupOutpatient individuals with stable chest pain and intermediate pre-test probability meeting guideline criteria for noninvasive testing.

Anomalous artery subgroupIndividuals with clinical suspicion for anomalous native coronary arteries (rare, ~1% prevalence on angiography).

CCTA — alternate / key terms

Alternate termsCoronary CT angiography; coronary computed tomography angiography (CCTA); contrast-enhanced coronary CT.

Common abbreviationCCTA (contrast-enhanced coronary computed tomography angiography).

Procedure codeAssociated CPT code: 75574 (CCTA with contrast and 3D postprocessing) referenced in policy coding section.

ICA — invasive coronary angiography definition

DefinitionInvasive coronary angiography (ICA) is the catheter-based reference standard invasive test to confirm coronary artery stenosis.

RoleServes as the reference standard in diagnostic accuracy studies comparing CCTA to invasive assessment.

Outcomes relationICA utilization is tracked as a downstream outcome after CCTA strategies in randomized trials and systematic reviews.

MACE — major adverse cardiac events definition

MACE definitionMajor adverse cardiac events (MACE) — composite clinical outcome commonly used in trials, including outcomes such as death, myocardial infarction, and other major cardiac events.

Use in studiesMACE used in short- and long-term follow-up of randomized trials evaluating CCTA strategies.

ReportingTrial reports and follow-up studies tabulate MACE to assess clinical impact of diagnostic strategies.

CCTA — repeated definition entry

Definition (repeat)Contrast-enhanced coronary computed tomography angiography (CCTA): noninvasive CT imaging of coronary arteries performed with IV iodinated contrast to detect stenoses, plaque, and graft/stent status.

Clinical useUsed to rule out CAD in ED and to evaluate stable chest pain or anomalous coronary anatomy per guideline-concordant indications.

Technical noteImage quality may be limited by calcification, stents, high heart rate, or arrhythmia.

ICA — repeated definition entry

Definition (repeat)Invasive coronary angiography (ICA): catheter-based invasive reference standard for detecting coronary artery stenosis, used as comparator in diagnostic accuracy studies.

UseEmployed to confirm CCTA findings and as an outcome measure (ICA rates) in trials comparing diagnostic strategies.

Relation to CCTACCTA may reduce or increase ICA rates depending on trial and comparator strategies.

CCTA — repeated definition entry

Outcomes emphasizedMortality, diagnostic accuracy, and utilization of invasive coronary angiography (ICA), assessed in initial days after ED admission and over longer-term follow-up.

Time horizonsShort-term (days to months) for ED rule-out; longer-term (years) for event rates and MACE assessment.

Utilization measuresLength of stay, downstream testing, ICA and revascularization rates, medication changes.

ICA — repeated definition entry

Definition (repeat)Contrast-enhanced coronary CT angiography (CCTA): noninvasive CT imaging performed with IV iodinated contrast to visualize coronary arteries and related cardiac structures.

IndicationsDiagnostic evaluation of suspected CAD, graft patency, stent/graft assessment, and delineation of anomalous coronary arteries when clinically suspected.

Includes3D postprocessing when performed according to procedure coding (eg, CPT 75574).

Clinically Valid — definition

Clinically validA test must detect presence or absence of a condition, risk of developing a condition, or treatment response (definition of 'Clinically Valid').

ImplicationClinical validity is required for a diagnostic test to be considered reliable for identifying disease status in patients.

Evidence standardStudies used to establish clinical validity should include appropriate reference standards and report marketed technology accuracy.

Clinically Useful — definition

Clinically usefulA test is clinically useful if results inform management decisions that improve net health outcomes by guiding correct or more effective therapy or avoiding unnecessary therapy/testing.

ApplicationClinical utility requires evidence that use of test results changes management and improves outcomes (eg, reduces MACE, mortality, or unnecessary procedures).

Evidence requirementRandomized trials or comparative studies demonstrating outcome differences strengthen claims of clinical usefulness.

CCTA — additional definition entries

Additional notesCCTA is described interchangeably as coronary CT angiography, contrast-enhanced coronary CT, and CCTA across the document.

TechniqueInvolves volumetric acquisition with IV iodinated contrast and may include 3D postprocessing for anatomical assessment.

LimitationsImage quality and applicability depend on patient factors (eg, heart rate, calcification, stents) and scanner technology.

CCTA — contrast-enhanced CTA definition

Contrast-enhanced CTACT technique using iodinated intravascular contrast to visualize coronary artery lumen and stenoses for evaluation of CAD and related indications.

Protocol implicationTrials and diagnostic studies assume contrast-enhanced protocols to assess lumen and plaque characteristics.

Policy coveragePolicy covers contrast-enhanced CCTA (code 75574) including 3D postprocessing when performed according to the Policy section.

Guideline documents — major society guideline documents cited

Major guidelines citedAHA/ACC guidelines and SCCT expert consensus documents are cited (eg, 2021 SCCT consensus; 2021 AHA/ACC chest pain guideline).

Other guidanceNICE guidance (CG95) and expert consensus statements on CCTA use in acute chest pain are referenced.

ImplicationPolicy references guideline-based pretest probability and recommendations for CCTA use in specified clinical scenarios.

Prior Authorization Guidance

Prior Authorization

Confirm indication and rationale for prior authorization

Prior authorization should confirm the indication (ED rule‑out or stable intermediate‑risk) and documentation of the rationale for choosing CCTA versus alternatives before approving imaging.

Provide clinical indication (ED acute chest pain or stable chest pain) and rationale for CCTA in authorization requests.
Include pretest probability and guideline alignment where relevant.

Prior Authorization

Prior authorization: stable chest pain intermediate‑risk

For stable chest pain prior authorization, ensure documentation shows the patient is intermediate pretest risk and that CCTA is being used as an alternative to other noninvasive tests per guidelines.

Include pretest probability assessment and guideline-based justification in the authorization submission.

Prior Authorization

Prior authorization for anomalous coronary arteries: justify anatomic need

For suspected anomalous coronary arteries, prior authorization may require documentation justifying CCTA use for anatomic delineation because no RCT evidence exists for clinical utility in this indication.

Explain why noninvasive anatomic delineation with CCTA is necessary and why other modalities are insufficient.
Acknowledge evidence is from case series without RCT outcomes.

Billing Rule

CPT 75574 medical necessity tied to Policy and contract

As determined by payer policy and the member contract, CPT 75574 must be performed according to the Policy section to be considered medically necessary; verify member contract and authorization rules.

Confirm member contract benefits and any payer-specific prior authorization or documentation requirements prior to service.
Ensure performance and documentation of 75574 align with Policy indications.

Background and Evidence Context

Background: Contrast-enhanced coronary computed tomography angiography (CCTA) is a noninvasive imaging technique using intravenously administered iodinated contrast and high-resolution, rapid CT acquisition to obtain volumetric images of the coronary arteries. CCTA visualizes coronary anatomy and atherosclerotic plaque and can be used as an anatomic alternative to functional stress testing or invasive angiography in selected clinical scenarios.

inv-06: CCTA diagnostic accuracy and trial outcome summary (also relevant background evidence)

Diagnostic accuracy summary: Meta-analyses and systematic reviews report high sensitivity (>95%) of CCTA for detecting anatomic coronary disease and high sensitivity (98%) and specificity (97%) for vein graft patency in segment-level analyses.

Chunks 97,111

Trial outcomes summary: Randomized trials show CCTA strategies yield similar clinical outcomes to functional testing or usual care in many studies; CCTA may increase downstream ICA or revascularization in some comparisons and reduces length of stay and costs in ED settings.

Chunks 26,97

Policy Revision History

2025-12-09policy_reviewLatest

Latest document review date recorded in policy metadata; general content and references updated as of this review.

2022-11-09effective_date

Current effective date of the policy as listed in policy metadata.

2012-11-05policy_guideline_update

Policy Guidelines replaced previous verbiage with 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline language and updated rationale.

2006-01-10major_revision

Old policy language deleted and CTA was previously classified experimental/investigational for coronary artery evaluation; covered diagnosis note and references updated.

2006-09-01revision_effective

Consultant review noted CTA remained experimental/investigational pending additional evidence; rare specialized cases described as potentially appropriate.

2006-01-10revision

Revisions to 'Policy' section deleted old policy and added CTA experimental/investigational language for coronary artery evaluation; effective dates and covered diagnosis notes appended.

2006-09-01effective_change

Policy language updated after consultant review concluding coronary CT angiography remained experimental/investigational as of June 14, 2006; special-case scenarios noted.

2008-12-15coding_update

Updated Revisions and References sections with coding removals and other coding changes; effective 12-15-2008.

2009-08-11coding_and_header_update

Coding section updated and policy header added; 2009 update recorded in rationale and coding sections.

2010-01-01coding_addition

CPT code 75574 was added to the policy's Coding section.

2011-08-19policy_language_revision

Policy language updated to specify use of 64-slice or greater scanners for certain indications and other item changes.

2012-11-05guideline_incorporation

Policy Guidelines replaced prior verbiage with 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline recommendations and rationale updated.